The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells

Author： Arun Banu Akar Ugur Gutierrez-Barrera Angelica M. Hortobagyi Gabriel N. Ozpolat Bulent

E-ISSN： 1791-2423|47|1|262-268

ISSN： 1019-6439

Source： International Journal of Oncology, Vol.47, Iss.1, 2015-07, pp. : 262-268

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition

International Journal of Oncology, Vol. 44, Iss. 3, 2014-01 ,pp. : 735-744

Spandidos Publications

Access to resources Recommend Favorite

BRCA1 and BRCA2 in breast cancer

By Yang X. Lippman M.E.

Breast Cancer Research and Treatment, Vol. 54, Iss. 1, 1999-03 ,pp. : 1-10

Springer Publishing Company

Access to resources Recommend Favorite

PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers

By Stebbing Justin Ellis Paul Tutt Andrew

Future Oncology, Vol. 6, Iss. 4, 2010-04 ,pp. : 485-486

Future Medicine

Access to resources Recommend Favorite

The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo

Molecular Medicine Reports, Vol. 6, Iss. 4, 2012-01 ,pp. : 897-903

Spandidos Publications

Access to resources Recommend Favorite

Mutation analysis of BRCA1 and BRCA2 in Turkish cancer families: a novel mutation BRCA2 3414del4 found in male breast cancer

By Balci A. Huusko P. Paakkonen K. Launonen V. Uner A. Ekmekci A. Winqvist R.

European Journal of Cancer, Vol. 35, Iss. 5, 1999-05 ,pp. : 707-710

Elsevier

Access to resources Recommend Favorite